Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
Candidacy to receive treatment with docetaxel.

Crossover Inclusion Criteria:

Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
ECOG performance status 0-2

Exclusion Criteria:

Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
Active brain metastases.

Crossover Exclusion Criteria:

Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.